Evidence map›Paper›PMID 25641878›Full record

ReviewPediatric pulmonology2015

Novel outcome measures for clinical trials in cystic fibrosis.

Harm A W M Tiddens, Michael Puderbach, Jose G Venegas, Felix Ratjen, Scott H Donaldson, Stephanie D Davis, Steven M Rowe, Scott D Sagel, Mark Higgins, David A Waltz

Open access · hybridAbstract readReview
In one paragraph

Review in Pediatric pulmonology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Assays of CFTR Function In Vitro, Ex Vivo and In Vivo.International journal of molecular sciences · 2022
    Review
  3. Article
  4. Review
  5. DNA Methylation atGenes · 2021
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Observational
  12. Article
  13. Cardiorespiratory and sensory responses to exercise in adults with mild cystic fibrosis.Journal of applied physiology (Bethesda, Md. : 1985) · 2015
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 5 countries.

Harm A W M TiddensDepartment of Pediatric Pulmonology and Allergology, Department of Radiology, Erasmus University Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
Michael PuderbachDepartment for Diagnostic and Interventional Radiology, Hufeland Klinikum, Bad Langensalza, Germany.
Jose G VenegasDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Felix RatjenDepartment of Pediatrics, Division of Respiratory Medicine, Hospital for Sick Children, University of Toronto, Toronto, Ontario.
Scott H DonaldsonDepartment of Medicine, University of North Carolina, Chapel Hill, North Carolina.
Stephanie D DavisDepartment of Pediatrics, James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana.
Steven M RoweDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Scott D SagelDepartment of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Denver, Colorado.
Mark HigginsVertex Pharmaceuticals Europe, Abingdon, UK.
David A WaltzVertex Pharmaceuticals, Boston, Massachusetts.
Children's Hospital Colorado · USErasmus MC · NLMassachusetts General Hospital · USResearch Centre of Medical Technology and Biotechnology · DERiley Hospital for Children · USUniversity of Alabama at Birmingham · USUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CAVertex Pharmaceuticals (United Kingdom) · GBVertex Pharmaceuticals (United States) · US

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
NCATS NIH HHS UL1 TR001082
6 · The paper itself

Abstract

Cystic fibrosis (CF) is a common inherited condition caused by mutations in the gene encoding the CF transmembrane regulator protein. With increased understanding of the molecular mechanisms underlying CF and the development of new therapies there comes the need to develop new outcome measures to assess the disease, its progression and response to treatment. As there are limitations to the current endpoints accepted for regulatory purposes, a workshop to discuss novel endpoints for clinical trials in CF was held in Anaheim, California in November 2011. The pros and cons of novel outcome measures with potential utility for evaluation of novel treatments in CF were critically evaluated. The highlights of the 2011 workshop and subsequent advances in technologies and techniques that could be used to inform the development of clinical trial endpoints are summarized in this review. Pediatr Pulmonol. © 2014 The Authors. Pediatric Pulmonology published by Wiley Periodicals, Inc.

Indexed as

CFTR activitycystic fibrosisendpointsimagingoutcome measuressputum biomarkers

Identifiers

PMID25641878
PMCPMC4365726
OpenAlexW1481320494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.